News & Events

• Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
  Published on 2022-08-04
• Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
  Published on 2022-08-03
• Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
  Published on 2022-07-28
• Vedanta Biosciences to Present at Upcoming Investor Conferences
  Published on 2022-07-07
• Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
  Published on 2022-06-30
• Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
  Published on 2022-06-28
• Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
  Published on 2022-06-28
• Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
  Published on 2022-06-22
• Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
  Published on 2022-06-08
• Microba and Ginkgo commence therapeutics program
  Published on 2022-06-07
• Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
  Published on 2022-06-07
• Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
  Published on 2022-06-01
• Microba appoints CRO for IBD Clinical Trial
  Published on 2022-05-26
• Microba signs partnership with nib-backed Midnight Health
  Published on 2022-05-25
• Microbiome and Bile Acid Restoration was Consistent Across Three Clinical Trials of Rbx2660 for Recurrent Clostridioides Difficile Infection: A Combined Analysis
  Published on 2022-05-24